IRB #

STUDY00019829

Title

[NCI CIRB] EA6174: A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Principal Investigator

Matthew Taylor

Study Purpose

The purpose of this study is to compare Overall Survival (OS) and Recurrence Free Survival (RFS) between patients with completely resected Merkel Cell Carcinoma randomized to MK-3475 (Pembrolizumab) or standard of care observation.

Medical Condition(s)

Completely Resected Merkel Cell Carcinoma

Eligibility Criteria

Eligibility criteria highlighted below:

1- histological confirmation of diagnosis of Merkel cell carcinoma (MCC), pathologic stages (AJCC version 8) I-IIIb
2- disease-free status & no currently present metastases
3- no previous systemic therapy or radiation therapy for Merkel cell carcinoma

A complete list of the eligibility criteria can be found in section 3.0 of the protocol

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

5 years from the time of study entry

Minors Included

No

Contact

Knight Information Line - trials@ohsu.edu or 503-494-1080

Sponsor

ECOG - ACRIN

Recruitment End

07/31/2021

Compensation Provided

No


Go Back